With a robust portfolio of 20+ peer-reviewed publications, my work has amassed over 1,400 citations (h-index: 8), driving innovations in gene editing, mRNA therapeutics, and nanoparticle delivery systems. Below are select highlights, showcasing impact in translational biotech.

Top Publications by Citation Impact

1. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingCell Reports (2018) – Co-author 918 citations | Cover feature | Altmetric score: 412 Pioneered LNP-based CRISPR delivery for sustained (>1 year) liver editing in NHPs—foundational for base-editing platforms.

2. Functionalized Lipid-Like Nanoparticles for In Vivo mRNA Delivery and Base EditingScience Advances (2020) – Co-author 192 citations | Faculty of 1000 Prime selection Developed ionizable lipid libraries enabling first non-hepatic base editing in muscle and lung tissues.

3. Knockdown of β-Catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In VivoMolecular Therapy (2014) – Co-author 70 citations Advanced siRNA formulations for oncology, demonstrating tumor reduction in preclinical models at Dicerna Pharmaceuticals.

4. Evaluation of Cytosine Base Editing and Adenine Base Editing as a Potential Treatment for Alpha-1 Antitrypsin DeficiencyMolecular Therapy (2022) – Co-author 36 citations Validated base-editing efficacy (>50% protein correction) in humanized models, informing clinical strategies for genetic liver diseases.

(Full list of 20 publications available on Google Scholar. Additional works span polymer science, drug delivery barriers, and fatigue mechanics, with contributions to ACS Nano, Applied Physics Letters, and more.)

These publications underscore my commitment to bridging lab discoveries with clinical realities—fueling 12+ active programs in mRNA-LNP, AAV, and LVV modalities.

Explore collaborations or consulting: aalok.shah@bioaiconsulting.com | 617.610.5840